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Abstract: Eukaryotic translation is a complex process composed of three main steps: 
initiation, elongation, and termination. During infections by RNA- and DNA-viruses, the 
eukaryotic translation machinery is used to assure optimal viral protein synthesis. Human 
immunodeficiency virus type I (HIV-1) uses several non-canonical pathways to translate its 
own proteins, such as leaky scanning, frameshifting, shunt, and cap-independent mechanisms. 
Moreover, HIV-1 modulates the host translation machinery by targeting key translation factors 
and overcomes different cellular obstacles that affect protein translation. In this review,  
we describe how HIV-1 proteins target several components of the eukaryotic translation 
machinery, which consequently improves viral translation and replication. 









Eukaryotic translation is a complex process orchestrated by a wide range of players, including several 
protein factors and three classes of RNA (ribosomal RNA (rRNA), transfer RNA (tRNA), and messenger 
RNA (mRNA)). This process is comprised of three main steps: initiation, elongation and termination. 
Immediately after transcription, mRNAs are maturated and exported through the nuclear pores to the 
cytoplasm. Once in the cytoplasm, cap-dependent translation is initiated by the recruitment of the small 
ribosomal subunit (40S), which scans along the mRNA until it finds an initiation codon. At this point, 
the large ribosomal subunit (60S) is engaged to decode the mRNA and assembles amino acids to 
synthesize proteins. The elongation step is completed when the ribosome reaches a stop codon that 
triggers the termination step. Finally, the components of the translational machinery are recycled for 
further protein translation. 
Optimal viral protein synthesis often occurs at the expense of cellular proteins and many viruses have 
evolved mechanisms that redirect and control the eukaryotic translational machinery. In these cases, viral 
factors can target the initiation, elongation and termination steps through interactions with key translation 
factors and mechanisms, which interfere with or disrupt the host translation machinery.  
The HIV-1 proteins are mainly synthesized by a cap-dependent mechanism. Nonetheless, different 
pathways such as leaky scanning, frameshifting, ribosome shunting, and cap-independent mechanisms  
are used to complete translation of the viral proteome. Moreover, HIV-1 has evolved sophisticated 
strategies to overcome cellular barriers that affect viral protein translation. This is the case of ribosomal 
scanning inhibition due to highly structured RNA elements and cap-dependent translation inhibition 
triggered by host immune responses. In this review, we focus on the HIV-1 functions that are essential 
to control the cellular translation apparatus in order to improve translation of viral proteins at the expense 
of cellular factors. 
2. Overview of Eukaryotic Translation 
2.1 Translation Initiation 
2.1.1. Pre-Initiation Complex Assembly and mRNA Activation 
Prior to translation initiation, the 5'-end of nascent mRNAs are capped with a 7-methylguanosine (m7G) 
and subsequently polyadenylated at their 3'-end immediately after transcription. The m7G cap is then 
recognized by the cap-binding complex (CBC), which is composed by the cap-binding proteins 80 and 20 
(CBP80/20) [1]. Messenger RNA export effectors (exon-exon junction complex (EJC) and SR proteins) 
are then loaded on mature mRNA molecules during the splicing events. These adaptors molecules allow 
the recruitment of the NXF1/NXT1 heterodimer, which mediates the export of the messenger 
ribonucleoprotein (mRNP) from the nucleus to the cytoplasm through the nuclear pores via interactions 
with nucleoporins [2,3] (Figure 1, steps 1–2). 
  




Figure 1. Eukaryotic translation initiation. mRNA maturation and nuclear export precede 
translation initiation (steps 1 and 2). Once in the cytoplasm, mRNA is activated (step 3) and 
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43S PIC formation takes place (step 4 to 5). The mRNA recruits the 43S PIC and scanning 
begins until an initiation codon is detected (step 6). At this point, the 48S initiation complex 
is formed and the 60S subunit is recruited to form the ribosome 80S complex (step 7 to 9). 
HIV-1 viral functions important to control the eukaryotic translation initiation are shown. 
(A) Unspliced and singly-spliced viral mRNAs could be translated due to the ability of the 
CBC to activate mRNA during translation initiation (green line); (B) HIV-1 protease partially 
inhibits translation initiation by targeting PABP, eIF3 and eIF4G (red lines); (C) Vpr-induced 
G2/M arrest indirectly inhibits host protein translation by targeting eIF4E activity (red line); 
(D) HIV-Tat protein and high concentration of HIV-1 TAR element indirectly promote viral 
translation by blocking PKR activity (red line). PKR phosphorylates eIF2α to block its 
recycling for ongoing translation, resulting in a potent translation inhibition of cellular and 
viral mRNA. 
Once in the cytoplasm, mRNAs undergo a CBC-mediated pioneer round of translation, which is 
important for the quality control of the transcript [4]. CBC is then displaced from the m7G and mRNAs 
are activated by the eukaryotic initiation factor 4F complex (composed of eIF4E, eIF4G and eIF4A) and 
eIF4B (Figure 1, step 3). Thus, mRNA acquires a “closed-loop” structure, required for an optimal mRNA 
recruitment into the 43S pre-initiation complex (PIC) (Figure 1, step 6). This conformation is achieved 
by the simultaneous binding of PABP (Poly(A)-binding protein) and eIF4E to eIF4G [5]. 
In parallel, ternary complex (TC) formation occurs through the assembly of the initiator methionyl-tRNA 
(Met-tRNAiMet), eIF2 and a GTP molecule (Figure 1, step 4). The TC is then recruited to the ribosomal 
subunit 40S to assemble the 43S PIC (Figure 1, step 5). In this process, other eIFs (eIF1, 1A, 3 and 5) are 
required to promote TC binding to the 40S subunit [6]. 
2.1.2. Initiation Codon Recognition and 80S Complex Formation 
Once the mRNA has been loaded on the 43S PIC, this complex scans the 5' untranslated region (5'UTR) 
until it recognizes a start codon (AUG) by complementarity with the anticodon of the Met-tRNAi. To 
prevent incorrect base pairing of the Met-tRNAi to a non-AUG codon and to promote recognition of the 
correct start codon, 43S PIC employs a discriminatory sequence-based mechanism. This permissive 
sequence (GCC(A/G)CCAUGG) surrounding the start codon is termed Kozak consensus sequence and 
is principally composed of a purine at position −3 and a G at position +4 (the A of the AUG codon is 
designated as +1) [7–9]. Once the AUG start codon has been recognized and the 48S complex formation 
has been accomplished, eIF1 is ejected from the scanning complex (Figure 1, step 7) [10]. This in turn 
triggers hydrolysis of eIF2-bound GTP and Pi release by the eIF5 GTPase activity.  
These events cause the transition from an “open” to a “closed” conformation of the scanning complex, 
which stabilizes the binding of the Met-tRNAi with the AUG start codon [11]. At this point, the remaining 
factors are dissociated to allow the joining of the 60S subunit and 80S complex formation (Figure 1, step 8). 
This process is mediated by eIF5B which causes the dissociation of eIF3, eIF4B, eIF4F and eIF5, and 
eIF5B self-dissociates from the assembled 80S ribosome by its GTPase activity [12]. This reaction also 
triggers the release of eIF1A to finally forms an elongation competent 80S ribosome (Figure 1, step 9) [13]. 
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2.2. Translation Elongation and Termination 
After the AUG start codon has been identified and the formation of the 80S ribosome has been achieved, 
translation elongation begins [13]. 80S ribosome decodes the mRNA sequence and mediates the addition 
of amino acids to elongate the growing polypeptide chain. Elongation is accomplished by the eukaryotic 
elongation factors eEF1 (composed of eEF1A and eEF1B) and eEF2 (Figure 2) [14,15]. The eEF1A-GTP 
complex carries each aminoacylated tRNA to the 80S ribosome A site where it builds codon-anticodon 
interactions (Figure 2, step 1). After 80S ribosome-catalyzed peptide bond formation (Figure 2, step 2), 
eEF2 mediates 80S ribosome translocation through GTP hydrolysis (Figure 2, step 3) and the next round 
of amino acid incorporation begins (Figure 2, step 4). 
Polypeptide elongation continues until a stop codon triggers the translation termination step. This 
process is mediated by the eukaryotic translation termination factors eRF1 and eRF3 [16]. The eRF1 factor 
mediates stop codon recognition, while eRF3 potently stimulates peptide release. After protein release, 
eRF1 remains bound to the post-termination complex (post-TC), and in conjunction with the ATP-binding 
cassette protein ABCE1, dissociates the post-TC into the 60S subunit, and the tRNA- and mRNA-bound 
40S subunit [17]. 
3. HIV-1 Takes Advantage of the Host Translation Machinery 
3.1. Overcoming Ribosome Scanning Barriers 
All spliced and unspliced HIV-1 transcripts possess the same 289 nt long 5'UTR. Because this region 
presents several highly structured motifs such as the trans-activation responsive (TAR) RNA element, the 
unwinding step of the ribosomal scanning process is expected to be inefficient [18]. Soto-Rifo et al. [19] 
have shown that RNA helicase DDX3 is required in order to overcome this constraint. DDX3 directly 
binds to the HIV-1 5'UTR and interacts with eIF4G and PABP to promote translation initiation of HIV-1 
genomic RNA [19], and mediates pre-initiation complex assembly in an ATP-dependent manner. In this 
process, the HIV-1 genomic RNA seems to be located in large cytoplasmic RNA granules alongside with 
DDX3, eIF4G and PABP, but not with CBP20/80 and eIF4E [20]. 
In vitro experiments revealed that cytoplasmic DDX3 is able to bind the m7G cap independently of 
eIF4E, showing that DDX3 could promote the formation of a pre-initiation complex in the absence of 
eIF4E. Thus, DDX3 substitutes for eIF4E to stimulate compartmentalized translation initiation of HIV-1 
unspliced mRNA [20]. Groom et al. [21], by using an in vitro transcription/translation assay from rabbit 
reticulocyte lysates, have demonstrated that Rev, which interacts with DDX3, stimulates translation of 
HIV-1 mRNAs at low concentration. This stimulation is dependent on a Rev binding site, in addition to 
the RRE, present in the internal loop B of stem-loop 1 (SL1) of HIV-1 RNA packaging signal [22]. On the 
contrary, at a high concentration, Rev inhibits mRNA translation in a non-specific manner. In this 
process, Rev may bind mRNAs and block ribosomal scanning by a mechanism that remains to be 
elucidated [21]. Lai et al. [23] have shown that DDX3 is recruited to the TAR region through the 
interaction with the Tat protein in order to promote HIV-1 mRNA translation. 




Figure 2. Eukaryotic translation elongation. eEF1A-GTP transports the aminoacylated tRNAs 
into the A site of the 80S ribosome and eEF1A-GDP is re-activated by eEF1B (step 1). The 
80S ribosome-mediated peptide bond formation (step 2) precedes ribosome translocation 
mediated by eEF2 (step 3). Finally, the ribosome begins another cycle of peptide elongation 
(step 4). HIV-1 viral functions important to control the eukaryotic translation elongation are 
shown. (A) HIV-1 Pr55Gag interacts with eEF1A and induces translation inhibition (red line); 
(B) HIV-1 Nef protein also interacts with eEF1A and mediates a nucleocytoplasmic 
relocalization of eEF1A (red line); (C) The HIV-1 RTC recruits eEF1 to stimulate late steps 
of the HIV-1 reverse transcription process (green line). 
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Other cellular proteins also bind the TAR element and promote viral translation. RNA Helicase A 
(RHA) binds to the TAR region in vitro and in vivo enhancing HIV-1 LTR-directed gene expression and 
viral production [24]. Dorin et al. [25] showed that the TAR RNA-binding Protein (TRBP) promotes 
translation of TAR-bearing RNAs independently of its ability to inhibit protein kinase RNA-activated 
(PKR). Other RNA-binding proteins have been shown to stimulate HIV-1 translation. This is the case 
with Staufen [26] and La autoantigen [27]. Both proteins stimulate translation of TAR-containing 
reporter transcripts. 
3.2. The Vpu-Env Bicistronic mRNA: Modulation of Ribosome Scanning Process 
As many other viruses, HIV-1 optimizes its genome coding capacity by translating different proteins 
from a common mRNA. This is the case of the bicistronic vpu-env mRNA which encodes both Vpu and 
Env proteins [28,29]. The coding sequences of Vpu and Env proteins are arranged so that the Vpu Open 
Reading Frame (ORF) precedes the Env coding sequence (Figure 3). Schwartz et al. [28,29] showed that 
the Env protein is synthesized by a leaky scanning mechanism in which the 43S PIC passes through the 
Vpu start codon. According to these authors, this modulation of the 43S PIC scanning process is achieved 
because the Vpu initiation codon is surrounded by a weak Kozak context [28,29]. As a result, mutations 
of the Vpu initiation codon that improve its Kozak context inhibit Env translation from the bicistronic 
vpu-env mRNA [28,29]. 
In contrast, by studying the 5'UTR of 16 alternatively spliced Env mRNAs, some of which also 
including the extra upstream Rev initiation codon, Anderson et al. [30] demonstrated that mutations in the 
upstream AUG codons of the Env ORF had little effect on Env synthesis. This suggests that Env translation 
is achieved via a discontinuous scanning mechanism such as ribosome shunting, a process in which the 
ribosome bypasses parts of the 5'UTR to reach a start codon. Indeed, Krummheuer et al. [31] reported 
that translation of Env protein was inconsistent with the leaky scanning model. Instead, Env translation is 
stimulated by a six-nucleotide upstream ORF (uORF) (Figure 3), which is located in the vpu start codon 
region. uORFs are short open reading frames located within the 5'UTR of a mRNA. Mutations of the 
start and stop codons of this uORF reduced Env protein translation five-fold [31].  
The authors suggest that this uORF acts as a ribosome pausing site supporting the ribosome shunting 
model [31]. 
3.3. The Fate of Unspliced HIV-1 mRNA 
3.3.1. Cap- and IRES-Dependent Translation Initiation  
The HIV-1 unspliced mRNA can initiate translation of Gag and Gag-Pol polyproteins either by a 
classical cap-dependent mechanism or by Internal Ribosome Entry Sites (IRES) [32–35]. Cap-dependent 
translation of HIV-1 unspliced mRNA has been observed in vitro [35] and ex vivo [33,36]. As described 
above, cap-dependent translation initiation relies on the recognition of the 5'UTR cap structure by the 
eIF4F complex to promote the recruitment of 43S PIC (Figure 1).  




Figure 3. The HIV-1 vpu-env bicistronic mRNA. A schematic diagram of the HIV-1 provirus 
genome is presented along with its primary 9 kb mRNA transcript. The vpu-env bicistronic 
mRNA is formed after splicing of the 9 kb mRNA. Start codon sequences of both vpu and env 
ORFs are presented and the upstream ORF that stimulates Env translation is boxed in green. 
IRESs present in several viral mRNAs (mainly picornaviruses and Hepatitis C virus) overcome a global 
translation down-regulation established by the cell during viral infection. The HIV-1 genomic mRNA 
presents two IRESs: one in the viral 5'UTR, named HIV-1 IRES [32] and a second within the gag coding 
region, known as HIV-1 Gag IRES [37] (Figure 4). The HIV-1 IRES has been characterized in a proviral 
wild-type HIV-1 clone (pNL4.3) [32], but also in the CXCR4 (X4)-tropic primary isolate HIV-LAI [38], 
and in viral RNA isolated from clinical samples [39], demonstrating the importance of these elements in 
HIV-1 replication. The cap structure and the HIV-1 IRES both drive translation of pr55Gag and pr160Gag/P°l. 
The minimal active HIV-1 IRES is harbored within the region spanning nucleotides 104 to 336 [32]. 
This region also contains several RNA motifs involved in different functions of the HIV-1 life cycle 
(Figure 4). 
The HIV-1 IRES has been shown to be implicated in different cellular states in which cap-dependent 
translation initiation is inhibited [18]. Monette et al. [34], by using in vitro artificial systems and  
HIV-1-expressing cells, reported that Pr55Gag translation was preserved at 70% when eIF4G and PABP, 
two main components of the cap-dependent translation initiation, were targeted by picornavirus proteases. 
Using a similar system, Amorim et al. [40] showed that HIV-1 protein synthesis is highly dependent on 
cap-initiation the first 24–48 h of viral replication, while at later time points IRES-dependent translation 
is needed to ensure viral particles production. HIV-1 IRES also drives viral structural protein synthesis 
during the G2/M cell cycle transition [32,41] and is stimulated by oxidative stress [38]. 




Figure 4. HIV-1 IRESs. HIV-1 IRES and HIV-1 Gag IRESs are represented. The 43S pre-initiation 
complex can mediate both cap-dependent and IRES-mediated translation initiation. 
Although the molecular mechanism of the HIV-1 IRES-mediated translation remains largely unknown, 
Plank et al. [42] demonstrated that the HIV-1 IRES is cell type-specific. Using a plasmid encoding a 
dual-luciferase reporter mRNA, the authors showed that the HIV-1 IRES activity was 4-fold higher in 
Jurkat T-cells than in HeLa cells. Based on the fact that all spliced and unspliced HIV-1 transcripts possess 
the same 289 nt long 5'UTR, the authors also demonstrated that vif, vpr, vpu, and nef transcripts can 
initiate translation by an IRES. Interestingly, despite the fact that all HIV-1 constructs contain the same 5' 
leader region, the IRES activity of these transcripts differ from the IRES-containing gag transcript [42]. 
Based on these results, Plank et al. [42] proposed a model in which the structure of the 5' leader region 
adopts several conformations to stimulate different processes in the viral replication cycle, such as RNA 
dimerization prior to packaging or IRES-mediated translation. Thus, cell type-specific ITAFs (IRES 
Trans-Acting Factors) could promote the structural conformation of the 5' leader region required for an 
optimal IRES activity. In vif, vpr, vpu or nef transcripts, the specific ITAFs bind regions of the 5'UTR 
common to all these transcripts to form a “Core IRES” that stimulate IRES-mediated translation. However, 
the IRES activity of these transcripts could be regulated by specific RNA sequences present downstream 
of the common 5'UTR [42]. 
Several cellular proteins have been reported as cellular factors increasing the HIV-1 IRES activity [18]: 
eIF5 [43], the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) [44] and the Rev-cofactors DDX3 
and hRIP [43]. On the contrary, the human embryonic lethal abnormal vision (ELAV)-like protein (HuR) 
has been identified as a negative regulator of the HIV-1 IRES activity [45]. Cis-acting elements have 
also been shown to negatively modulate HIV-1 IRES activity. Brasey et al. [32] showed that the Gag ORF 
impacts the HIV-1 IRES-mediated translation initiation in the context of a bi-cistronic mRNA. Gendron 
et al. [38] identified another region located upstream of the PBS, the IRES negative element (IRENE) 
that also negatively regulates the HIV-1 IRES activity (Figure 4). Recently, it was shown that the 
instability element 1 (INS-1), a cis-acting regulatory element present within the gag ORF, also inhibits 
HIV-1 IRES activity (Figure 4) [46]. Furthermore, several HIV-1 IRES ITAFs have been identified from 
G2/M-arrested cell extracts [41], including proteins that have already been identified to have a role in 
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HIV-1 replication, such as the high mobility group protein HMG-I/HMG-Y (HMG-I(Y)) [47] or the 
activated RNA polymerase II transcriptional co-activator p15 [48]. 
The HIV-1 Gag IRES mediates translation of both full length Pr55Gag polyprotein and a N-truncated 
40-kDa Gag (p40) isoform lacking the matrix domain [37,49]. Despite the fact that p40 is produced at a 
much lower level than Pr55Gag, this protein seems to be important in wild-type replication of HIV-1 in 
cultured cells [37]. Expression of p40 has also been observed in all HIV-1 clinical isolates from a large 
cohort of patients (n = 100) [18]. 
3.3.2. Ribosomal Frameshift 
The Gag-Pol polyprotein, which is synthesized at a ~1/10 ratio compared to Gag, is translated via  
a −1 nucleotide ribosomal frameshift [50,51]. This process is regulated by two main factors, a slippery 
heptanucleotide sequence (UUUUUUA) where the frameshift takes place, and a downstream RNA element 
called the frameshift stimulatory signal (FSS) that controls the frameshift efficiency (Figure 5) [52]. The 
shift places the gag termination codon into an out-of-frame context and translation continues toward the 
downstream pol sequence [50,51]. The structure of the FSS and its mechanistic mode of action are not 
well understood. It has recently been proposed that the −1 frameshift is promoted by 4 pseudoknots 
(PK1-4) present in the FSS [53,54]. However, ex virio SHAPE (Selective 2'-Hydroxyl Acylation analyzed 
by Primer Extension) experiments [55] and frameshifting assays [56] do not support this model. 
 
Figure 5. HIV-1 Ribosomal frameshift. A schematic diagram of the −1 nucleotide ribosomal 
frameshift. This process is mediated by a slippery heptanucleotide sequence (UUUUUUA) 
where the frameshift takes place, and an RNA element called the frameshift stimulatory 
signal (FSS). 
The most widely accepted model suggests that −1 frameshift is triggered when the FSS forces a small 
portion of the 80S complexes to make a pause. This pause forces the 80S complexes to shift one 
nucleotide backwards into the pol sequence [57–59]. Léger et al. [57] have proposed a model in which, 
after release of the eEF2-GDP complex from the ribosome, the two tRNAs cannot be translocated by 
three nucleotides (from P/A to E/P sites). Instead the two tRNAs are translocated only by two nucleotides 
due to the FSS. Consequently, the two tRNAs are trapped in an intermediate translocation state and 
frameshift is achieved [57]. This is supported by the cryo-EM structure resolved by Namy et al. [58], in 
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which the ribosome is stalled by the presence of the FSS. Additionally, Mouzakis et al. [56] have 
demonstrated that the base pairs important for this process are located at an 8 nt distance from the 
slippery sequence, which is consistent with the paused-ribosome model. 
Further studies have shown that the highly structured TAR element and the Tat protein modulate 
ribosomal frameshift [60,61]. Charbonneau et al. [61] demonstrated that the presence of the HIV-1 5'UTR 
in a reporter mRNA increases the −1 frameshift efficiency fourfold in Jurkat T-cells, compared to a 
control reporter with a short unstructured 5'UTR. This is associated with the presence of the TAR region 
within the 5'UTR [60,61]. This region slows down the rate of translation initiation during cap-dependent 
translation. As a consequence, the distance between ribosomes is larger and the FSS has more time to 
refold [60,61]. Thus, a structured FSS is required for an optimal −1 frameshift process. The increase in 
the −1 frameshift efficiency is antagonized by the HIV-1 Tat protein, which indirectly destabilizes TAR 
structure by increasing recruitment of RNA helicases, such as DDX3 [23]. Moreover, Lorgeoux et al. [62], 
using a dual-luciferase reporter assay, showed that the helicase DDX17 is required for −1 frameshift and 
for maintaining proper ratios of Gag vs. Gag-Pol proteins. 
3.4. Redirecting mRNA Activation 
In the G2/M phase of the cell cycle, cap-dependent translation is down-regulated by a cascade of events 
that lead to the disruption of the eIF4F complex, and thereby inhibition of the mRNA activation step 
(Figure 1, step 3) [63]. In this process, formation of the eIF4F complex is prevented by targeting of eIF4E. 
This factor is regulated by a family of translation inhibitor proteins, named the eIF4E-binding proteins 
(4E-BPs). After hypophosphorylation, 4E-BPs compete with eIF4G for the same binding site on eIF4E, 
preventing eIF4F complex assembly [63,64]. 
In HIV-1-infected cells, viral proteins alter cell function by affecting different cellular pathways. 
HIV-1 viral protein R (Vpr) has been identified as a viral protein capable of arresting cells in the G2/M 
phase. Vpr mediates G2/M arrest via a complex signaling cascade involving activation of the ataxia 
telangiectasia mutated and Rad3-related kinase (ATR) [65]. Vpr-induced G2/M arrest also inhibits host 
protein translation by a process involving the regulation of eIF4E activity (Figure 1C) [66]. 
Despite the global reduction of host protein synthesis by Vpr-induced G2/M arrest, translation of 
HIV-1 structural proteins is maintained [58]. RNA-coimmunoprecipitation experiments showed that 
full-length unspliced HIV-1 genomic RNA and singly spliced mRNAs are associated with CBC in contrast 
to multi-spliced viral and cellular mRNAs that are associated with eIF4E. Moreover, unspliced and 
singly-spliced viral mRNAs retain their interaction with CBC during translation and packaging. Based on 
these observations, Sharma et al. [66] hypothesized that unspliced and singly-spliced viral mRNAs are 
translated due to the ability of the CBC to activate mRNA during initiation (Figure 1A). Thus, CBC retention 
could allow viral protein synthesis while the global protein translation is inhibited by an eIF4E decrease.  
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3.5. Targeting Cellular Translation Factors 
During the HIV-1 replication cycle, viral proteins inhibit different translation factors. This is the case 
of the HIV-1 protease, which partially impairs cap-dependent protein translation, in addition to its main 
function during virion maturation. Ventoso et al. [67] were the first to report that HIV-1 protease is able 
to cleave the initiation factor eIF4G in cellula (Figure 1B), by using HIV-1 C8166 target cells. Further 
studies using rabbit reticulocyte lysates have demonstrated that HIV-1 protease not only cleaves eIF4G 
but also PABP (Figure 1B) [68–70]. Degradation of eIF4G and PABP leads to an inhibition of the cap- 
and PABP-dependent translation initiation [67–70]. Jäger et al. [71] reported that the HIV-1 protease also 
cleaves eIF3d (Figure 1B), a subunit of eIF3. This cleavage presents a similar efficiency to the one of the 
Pr55Gag. This may also promote inhibition of cap-dependent protein synthesis. 
In the early phases of HIV-1 replication, the HIV-1 TAR RNA element activates PKR, which mediates 
host translation inhibition [72]. PKR interacts with the TAR element, inducing PKR dimerization,  
auto-phosphorylation and activation. Activated PKR phosphorylates the alpha subunit of eIF2 (eIF2α), 
blocking its recycling for ongoing translation, resulting in a potent translation inhibition of cellular and 
viral mRNA [73]. HIV-1 indirectly prevents phosphorylation by targeting PKR. Indeed, the HIV-1 Tat 
protein directly interacts with PKR, thus, preventing auto-phosphorylation (Fig 1D) which is essential 
for function [72,74]. Moreover, during the late events of HIV-1 replication, PKR activity is inhibited by 
the high concentration of the HIV-1 TAR element (Fig 1D). Studies with TAR and other RNAs showed 
that high concentration of double-stranded RNA (dsRNA) inhibits PKR dimerization and therefore its 
activation [75]. PKR activation is further inhibited by HIV-induced mechanisms involving the cellular 
factors TRBP, Adenosine deaminase ADAR1 and a change in PACT function [72,76].  
Moreover, by using a yeast two-hybrid screen assay, Cimarelli and Luban [77] reported that the HIV-1 
Pr55Gag binds to eEF1A through its matrix (MA) and nucleocapsid (NC) domains. They demonstrated that 
this interaction requires RNA, and suggested that tRNA could probably mediate this interaction since 
both NC and eEF1A have been shown to bind tRNAs [78,79]. Thus, as cellular concentration of Pr55Gag 
increases in the cell, Pr55Gag association with eEF1A-tRNA complexes may induce translational inhibition 
(Figure 2A). As a consequence of this inhibition, viral genomic RNA could be released from the 
translation machinery. Subsequently, Pr55Gag interaction with the genomic RNA may lead to a further 
viral translation inhibition, thus stimulating RNA packaging into virions [77]. The authors also showed 
that both eEF1A and a truncated form of eEF1A of 34 to 36 kDa are incorporated into virions. In addition, 
eEF1A can also interact with the cellular cytoskeleton, suggesting a possible role of eEF1A in virion 
assembly and budding [80]. Despite these reports, direct evidence for a role of eEF1A in RNA packaging, 
virion assembly or viral particle budding remains to be demonstrated [81]. 
Similar to Pr55Gag, HIV-1 Nef protein also interacts with eEF1A and forms a Nef/eEF1A/tRNA 
complex. Thus, Nef mediates a nucleocytoplasmic relocalization of eEF1A and tRNAs to prevent  
stress-induced apoptosis in primary human macrophages (Figure 2B) [82]. Moreover, Warren et al. [83] 
have reported that the HIV-1 reverse transcription complex (RTC) recruits eEF1 to stimulate late steps 
of the HIV-1 reverse transcription process (Figure 2C). The eEF1 factor binds to the HIV-1 RTC through 
an interaction with reverse transcriptase (RT) and integrase (IN). This association enhances the stability 
of the RTC in the cytoplasm [83]. Nevertheless, further studies will be needed to establish whether eEF1 
functions synergistically with the components of the RTC, or independently during reverse transcription. 
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3.6. Inhibiting APOBEC3G Translation 
APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, or A3G) is a 
restriction factor that impairs HIV-1 replication [84]. A3G is incorporated into viral particles and during 
reverse transcription in the target cells, it converts cytidines into uridines in the (−) strand DNA. This 
will generate further reverse transcription and integration defects and potentially produce non-functional 
viral proteins. HIV-1 counteracts this cellular factor by at least two pathways involving the HIV-1 viral 
infectivity factor (Vif). First, binding of Vif to A3G allows the recruitment of an E3 ubiquitin ligase that 
mediates the poly-ubiquitination of A3G and its degradation through the proteasome pathway. Second, 
Vif impairs the translation of A3G mRNA through a putative mRNA-binding mechanism [85,86]. 
Mariani et al. [87] were the first to observe that Vif inhibits A3G translation and suggested that this 
repression may contribute to the reduction of A3G encapsidation. The authors reported that Vif causes 
a 4.6 fold reduction in A3G synthesis by pulse-chase metabolic labeling experiments. Additionally,  
Kao et al. [88] showed that Vif causes the reduction of cell-associated A3G by 20%–30% compared to up 
to 50-fold reduction in virus-associated protein. This result supports the idea that Vif functions at different 
levels to reduce the intracellular levels of A3G. A3G translational inhibition was finally confirmed by 
Stopak et al. [89]. By using kinetic analyses and in vitro transcription-translation experiments, the authors 
showed that Vif was capable of impairing A3G translation by approximately 30%–40% [89]. 
Based on these observations, we recently showed that Vif binds to A3G mRNA and inhibits its 
translation in vitro [86]. Indeed, filter binding assays and fluorescence titration experiments revealed 
that Vif tightly binds A3G mRNA. We also demonstrated that Vif is able to inhibit A3G translation in 
in vitro-coupled transcription/translation assays. In these experiments, Vif caused a two-fold reduction 
of A3G translation in a 5'UTR-dependent manner, most likely through mRNA binding and/or through its 
RNA chaperone activity [90,91]. These observations show that HIV-1 not only targets the host 
translational machinery to improve translation of its own proteins, but also inhibits translation of the 
host restriction factor A3G. 
4. Concluding Remarks  
HIV-1 has evolved several mechanisms that control the host translation machinery and overcome 
different obstacles in the cell, such as ribosomal scanning inhibition due to highly structured RNA elements 
and cap-dependent translation inhibition triggered by host immune responses. During this antiviral state 
triggered by the cell, HIV-1 proteins interact with the eukaryotic translation apparatus in different ways. 
Thus, these mechanisms not only promote translation of HIV-1 proteins, but also guarantee the fitness of 
newly produced viral particles by inhibiting A3G incorporation. It seems that the sophisticated functions 
presented in this review only represent a fraction of the strategies that have evolved by HIV-1 interaction 
with cellular functions, leading to a control of the host translation machinery during viral replication. 
Indeed, Jäger et al. [71] reported 497 interactions between 16 HIV-1 proteins and 435 human proteins. 
In addition, genome-wide techniques such as ribosome profiling [92] and/or iCLIP (individual-nucleotide 
resolution UV cross-linking and immunoprecipitation) [93] could be used, for example to identify HIV-1 
Vif mRNA targets and to understand how this protein inhibits translation of specific genes. Identifying 
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which cellular proteins of the translational eukaryotic machinery are targeted by HIV-1 will be crucial for 
a global understanding of the HIV-1 replication. 
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